GlassScriptPhysician profile
Anne K Voss
NPI 1801848395
$5,250.01
in general payments reported to CMS, 2019-2025
34 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,124 · 2022: $897 · 2023: $1,165 · 2024: $1,033 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $601.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $601.21 | 2021-2025 | |
| Lilly USA, LLC | $502.31 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $493.84 | 2022-2025 | Rexulti, Abilify Maintena, Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.40 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $394.45 | 2021-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $237.74 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $214.64 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $193.11 | 2022-2024 | Belsomra, Verquvo, Steglatro |
| Exact Sciences Corporation | $191.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $155.96 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $153.06 | 2021-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $134.75 | 2021-2024 | |
| Pfizer INC. | $132.44 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $110.96 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.51 | 2023-2025 | Caplyta |
| Lundbeck LLC | $82.14 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $59.82 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $58.02 | 2024-2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $53.83 | 2021-2023 | Ajovy |
| Axsome Therapeutics, INC. | $53.41 | 2023-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $46.74 | 2021-2023 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $40.60 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.32 | 2022-2024 | |
| Eisai INC. | $32.14 | 2021 | |
| Tris Pharma INC | $18.71 | 2024 | Dyanavel Xr |
| Cranial Technologies, INC | $18.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.39 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $15.28 | 2024 | Trintellix |
| Neurelis, INC. | $14.58 | 2023 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $14.10 | 2023 | Eliquis |
| Sumitomo Pharma America, INC. | $13.39 | 2023 | Gemtesa |
| Philips North America LLC | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.